Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human RMC Therapeutic Vaccine
- Development stage
- Preclinical
- Lead developer
- Calviri
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intramuscular
01
Overview
The Human RMC Therapeutic Vaccine is an off-the-shelf cancer vaccine being developed by Calviri for the treatment of renal medullary cancer (RMC), a rare and aggressive malignancy. It is based on the proprietary RNA-Error Derived Neoantigens (REDNs) platform, which identifies shared frameshift peptides generated by tumor-specific RNA processing errors. Unlike personalized neoantigen vaccines, this therapeutic is designed as a pre-made product targeting antigens common across RMC patients. The vaccine is currently in development, with plans for a first-in-human clinical trial in collaboration with MD Anderson Cancer Center.
- Other names
- RMC Therapeutic Vaccine
02
Targets
REDN (RNA-error derived neoantigen frameshift peptide)pMHC-I (Peptide–MHC class I complex)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Human RMC Therapeutic Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human RMC Therapeutic Vaccine.